Evidence map›Paper›PMID 40989918›Full record

ArticleComputational and structural biotechnology journal2025

Internal validation strategy for high dimensional prognosis model: A simulation study and application to transcriptomic in head and neck tumors.

Antoine Dubray-Vautrin, Victor Gravrand, Grégoire Marret, Constance Lamy, Jerzy Klijanienko, Sophie Vacher, Ladidi Ahmanache, Maud Kamal, Olivier Choussy, Nicolas Servant and 3 more

Registry-linked trialAbstract read
In one paragraph

Article in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03017573 (Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03017573 narecruitingnot on this map

Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)

TypeinterventionalSponsorInstitut CurieRan2017 to 2032Enrolled1,050ConditionsOvarian Cancer, Triple-Negative Breast Cancer, Head and Neck Cancer, Cervical CancerArmsTumor biopsies / Tumor surgery, Blood withdrawal
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. An Interpretable Omics-to-Image Transformer Framework for Cancer Prognosis Prediction.Computational and structural biotechnology journal · 2026
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Antoine Dubray-VautrinInstitut Curie, INSERM, Saint Cloud U1331, France.
Victor GravrandGenetics Department, Institut Curie, Paris, France.
Grégoire MarretDepartment of Drug Development and innovation (D3i), Paris, France.
Constance LamyDepartment of Drug Development and innovation (D3i), Paris, France.
Jerzy KlijanienkoDepartment of pathology, Institut Curie, Paris, France.
Sophie VacherGenetics Department, Institut Curie, Paris, France.
Ladidi AhmanacheGenetics Department, Institut Curie, Paris, France.
Maud KamalDepartment of Drug Development and innovation (D3i), Paris, France.
Olivier ChoussyDepartment of surgical oncology, Institut Curie, Paris, France.
Nicolas ServantInstitut Curie, INSERM, Saint Cloud U1331, France.
Célia DupainDepartment of Drug Development and innovation (D3i), Paris, France.
Christophe Le TourneauInstitut Curie, INSERM, Saint Cloud U1331, France.
Jimmy MullaertInstitut Curie, INSERM, Saint Cloud U1331, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Predictive models using high-dimensional data, such as genomics and transcriptomics, are increasingly used in oncology for time-to-event endpoints. Internal validation of these models is crucial to mitigate optimism bias prior to external validation. Common strategies include train-test, bootstrap, and (nested) cross-validation. However, no benchmark exists for these methods in high-dimensional settings. We aimed to compare these strategies and provide recommendations in the field of transcriptomic analysis. Method: A simulation study was conducted using data from the SCANDARE head and neck cohort (NCT03017573) including n = 76 patients. Simulated datasets included clinical variables (age, sex, HPV status, TNM staging), transcriptomic data (15,000 transcripts), and disease-free survival, with a realistic cumulative baseline hazard. Sample sizes of 50, 75, 100, 500, and 1000 were simulated, with 100 replicates each. Cox penalized regression was performed for model selection, followed by train-test 70 % training), bootstrap (100 iterations), 5-fold cross-validation, and nested cross-validation (5 ×5) to assess discriminative (time-dependent AUC and C-Index) and calibration (3-year integrated Brier Score) performance. Results: Train-test validation showed unstable performance. Conventional bootstrap was over-optimistic, while the 0.632 + bootstrap was overly pessimistic, particularly with small samples (n = 50 to n = 100). The k-fold cross-validation and nested cross-validation improved performance with larger sample sizes, with k-fold cross-validation demonstrating greater stability. Nested cross-validation showed performance fluctuations depending on the regularization method for model development. Conclusion: The K-fold cross-validation and nested cross-validation are recommended for internal validation of Cox penalized models in high-dimensional time-to-event settings. These methods offer greater stability and reliability compared to train-test or bootstrap approaches, particularly when sample sizes are sufficient.

Indexed as

Head and neckPenalized regressionPrognosisSimulationTranscriptomicValidation

Identifiers

PMID40989918
PMCPMC12451366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.